Orell Mielke
Marburg An Der Lahn, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Automatically quantified follow-up imaging biomarkers predict clinical outcomes after acute ischemic stroke.
Journal: Frontiers in neurology
Published: August 19, 2024
Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.
Journal: Journal of the peripheral nervous system : JPNS
Published: January 25, 2022
Incidence and risk factors for intravenous immunoglobulin-related hemolysis: A systematic review of clinical trial and real-world populations.
Journal: Transfusion
Published: October 20, 2021
Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.
Journal: Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
Published: January 12, 2021
Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy.
Journal: CPT: pharmacometrics & systems pharmacology
Published: September 10, 2020
Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) study.
Journal: Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
Published: June 23, 2020
Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review.
Journal: Journal of the peripheral nervous system : JPNS
Published: May 15, 2020
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: March 07, 2019
Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.
Journal: European journal of neurology
Published: January 29, 2019
Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
Journal: Journal of the peripheral nervous system : JPNS
Published: October 10, 2018
Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
Journal: Journal of the peripheral nervous system : JPNS
Published: September 03, 2018
IgPro20, the Polyneuropathy and Treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG.
Journal: Immunotherapy
Published: May 17, 2018
Last Updated: 09/26/2026